Barclays Sets $106 Target for Ionis Pharmaceuticals, Forecasting 45% Upside

Barclays analysts have issued a bullish outlook for Ionis Pharmaceuticals (IONS), setting a new price target of $106 per share. This target implies a potential upside of approximately 45% from the stock's current trading level of $72.70. While the stock has experienced a 6.12% decline since the beginning of 2026, its long-term performance remains robust with a 137.52% gain over the past year. Currently, the shares are trading about 7.20% below their recent one-month high, presenting what analysts view as a significant valuation gap. The positive projection reflects institutional confidence in the company's growth prospects within the biotechnology sector. Investors are closely monitoring the NASDAQ-listed firm as it navigates recent market volatility and analyst re-ratings.

Sources:247wallst.cominvesting.combenzinga.comtipranks.commarketbeat.comstreetinsider.com